Analysts expect Veradermics, Incorporated to report Q1 2026 revenue of $0.00 and an EPS loss of $0.56, with the current stock price of $127.42 sitting slightly below the average analyst target of $132.80. The primary focus for investors remains the clinical trajectory and upcoming data readouts for VDPHL01, an oral extended-release therapeutic targeting the multibillion-dollar pattern hair loss market.
Veradermics recently fortified its balance sheet through an upsized IPO and subsequent financing totaling $767 million, which management indicates provides a cash runway into 2030. Market participants are specifically monitoring Research and Development expenditure and confirmatory results from the Phase 3 Study 304 to validate the robust efficacy signals seen in earlier trials.